Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

OBJECTIVE: Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Turk J Haematol
Hlavní autoři: Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M. Cem, Öngören, Şeniz, Eşkazan, A. Emre, Soysal, Teoman, Aydın, Yıldız
Médium: Artigo
Jazyk:Inglês
Vydáno: Galenos Publishing 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5544042/
https://ncbi.nlm.nih.gov/pubmed/28270368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2016.0397
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky